NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

September 19, 2019

Sylvia Adams, MD, discusses the biology of triple-negative breast cancer, data sparking excitement in the field, and intriguing trials on the horizon.

September 10, 2019

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

September 10, 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the next steps that have to be taken to validate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker in BRAF-mutant melanoma.

August 14, 2019

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, director, Breast Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses the use of trastuzumab biosimilars in the treatment of patients with breast cancer.

July 30, 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the predictive value of circulating tumor DNA (ctDNA) in BRAF-mutant melanoma.

July 23, 2019

David Polsky, MD, PhD, discusses findings from an analysis in patients with BRAF-mutant, unresectable, metastatic melanoma, as well as the next steps for validating these findings and potentially using circulating tumor DNA to help inform treatment decisions.

July 11, 2019

Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the next steps for research regarding the phase II KEYNOTE-057 trial in nonmuscle–invasive bladder cancer (NMIBC).

July 02, 2019

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.

May 30, 2019

Francisco J. Esteva, MD, PhD, director, Breast Medical Oncology, professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the prevalence of precision medicine in the treatment of patients with breast cancer.

May 29, 2019

Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the future of immunotherapy in bladder cancer.

May 28, 2019

Gary D. Steinberg, MD, a nationally recognized specialist in the surgical management of bladder cancer, has been named director of the Goldstein Urology Bladder Cancer Program at NYU Langone Health.

May 22, 2019

Arjun V. Balar, MD, highlights the KEYNOTE-057 study findings and provided insight into the role of immunotherapy in bladder cancer.

May 22, 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in patients with bladder cancer.

April 16, 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses the improved outlook for patients with metastatic bladder cancer.

April 10, 2019

Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the importance of specialized care in lung cancer and sheds light on the current outlook of the disease.

March 27, 2019

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the management of immune-related adverse events (irAEs) in patients with lung cancer.

March 20, 2019

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses the use of dacomitinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

March 15, 2019

The National Cancer Institute (NCI) has designated NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center as a Comprehensive Cancer Center, the highest rank awarded by the NCI. Perlmutter joins an elite group of 50 cancer centers across the country that have earned this distinction.

March 07, 2019

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the utility of liquid biopsies in lung cancer.

March 06, 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses findings from the KEYNOTE-057 study presented at the 2019 Genitourinary Cancers Symposium.